Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life

Neurology

Volumn 65, Issue 12 SUPPL. 4, 2005, Pages

  Lipton, R B ^a   Bigal, M E ^a,b   Stewart, W F ^c,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c AdvancePCS   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIMIGRAINE AGENT; ELETRIPTAN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN;

ABSENTEEISM; ACUTE DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COMPARATIVE STUDY; COMPARATOR DESIGN; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DISABILITY; DRUG EFFICACY; EPISODIC MONOPHASIC PAIN DISORDER; HEADACHE; HEALTH CARE COST; HUMAN; MIGRAINE; MIXED DESIGN; NEUROPATHIC PAIN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN; PARALLEL DESIGN; POSTOPERATIVE PAIN; POSTTRAUMATIC PAIN; PRE POST DESIGN; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RANDOM INSERTION OF PLACEBO DESIGN; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SUSTAINED RESPONSE; TREATMENT RESPONSE; TWO PERIOD CROSSOVER DESIGN; USUAL CARE DESIGN; CHRONIC DISEASE; HEADACHE AND FACIAL PAIN; METHODOLOGY; PAIN ASSESSMENT; PATIENT SATISFACTION; STATISTICS; TREATMENT OUTCOME;

CHRONIC DISEASE; DISABILITY EVALUATION; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT OUTCOME;

EID: 33645095241     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.65.12_suppl_4.s50     Document Type: Review

References (61)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-69.
2. Lipton RB, Stewart WF, Von Korff M. Burden of migraine: Societal costs and therapeutic options. Neurology 1997;48(suppl 3):S4-9.
3. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-645.
4. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 1994;44 (suppl 4):24-39.
5. Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie IK, ed. Epidemiology of pain. Seattle: IASP Press, 1999:159-170.
6. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998;38:87-96.
7. Stang PE, Von Korff M. The diagnosis of headache in primary care: factors in the agreement of clinical and standardized diagnoses. Headache 1994;34:138-142.
8. Richard A, Massiou H, Herrmann MA. Frequency and profile of migraine patients seen by general practitioners. Semin Hosp Paris 1999;75:440-446.
9. Lipton RB, Amatniek JC, Ferrari MD, Gross M. Migraine. Identifying and removing barriers to care. Neurology 1994;44(suppl 4):63-68.
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
11. Lipton RB. Methodologic issues in acute migraine clinical trials. Neurology 2000;55(suppl 2):3-7.
12. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002;346:257-269.
13. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-786.
14. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20:554-560.
15. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 1998;38:281-287.
16. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000;54:156-163.
17. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997;49:1210-1218.
18. Ferrari MD, Krista RI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1b/1d agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-1775.
19. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000; 20:588-596.
20. Block GA, Goldstein J, Polis A, Reines SA, Smith ME, The Rizatriptan Multicenter Study Groups. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache 1998;38:764-771.
21. Winner P, Ricalde O, Le Force B, Saper J, Margul B. Double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-184.
22. Cady R, Crawford G, Ahrens S, et al. Long-term efficacy and tolerability of rizatriptan wafers in migraine. MedGenMed 2001;3:1-8.
23. Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract 2000;54:281-286.
24. Lipton RB, Stewart WF, Cady R, et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000;40:783-791.
25. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002;42 (suppl 1):3-9.
26. Aurora SK. Headache recurrence as a criterion for assessing efficacy of triptans: a perspective. Headache 2002;42:70-79.
27. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-658.
28. International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998;38:173-183.
29. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled cross-over study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998;51:773-781.
30. Mathew NT, and the Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12.5mg for the treatment of acute migraine. Headache 2002;42:32-40.
31. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behavior, and medication use: a Canadian population survey. Can J Neurol Sci 1993;20:131-137.
32. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American Migraine study. Cephalalgia 1996;16:231-238.
33. Michel P, Dartigues JF, Lindousli A, Henry P. Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache 1997;37:71-78.
34. Von-Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology 1998;50:1741-1745.
35. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813-818.
36. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers Cephalalgia 1999;19:107-113.
37. Stewart WF, Lipton RB, Kolodner K, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41-52.
38. Lipton RB, Stewart WF, Stone AM, Lainez MJA, Sawyer JPC. Stratified care vs step care strategies for migraine: results of the Disability in Strategies of Care (DISC) Study. JAMA 2000;284:2599-2605.
39. Jacobson GP, Ramadan NM, Norris L, Newman CW. Headache disability inventory (HDI): short-term test-retest reliability and spouse perceptions. Headache 1995;35:534-549.
40. Pryse-Phillips W. Evaluating migraine disability: the headache impact test instrument in context. Can J Neurol Sci 2002;29(suppl 2):11-15.
41. Freitag F, Diamond S, Lyss H, et al. MIDAS as a healthcare utilization tool in the challenging patient. Cephalalgia 2000;20:365. Abstract.
42. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997,48(suppl 3):4-9.
43. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998;13:667-676.
44. Stewart WF, Lipton RB. Work-related disability: results from the American Migraine Study. Cephalalgia 1996;16:231-238.
45. Lipton RB, Stewart WF. Health-related quality of life in headache research. Headache 1995;35:447-448. Editorial.
46. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998;158:1013-1018.
47. Solomon GD, Skobieranda FG, Graff LA. Quality of life and well-being of headache patients: measurement by the Medical Outcomes Study Instrument. Headache 1993;33:351-358.
48. Lipton RB, Hamelsky SW, Stewart WF. Epidemiology and impact of migraine. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's headache and other head pain. New York: Oxford University Press, 2001: 85-107.
49. Tarlov A, Ware J, Greenfiels S, et al. The Medical Outcome Study: an application of methods for monitoring the results of medical care. JAMA 1989;262:920-930.
50. Solomon GD. Evolution of the measurement of quality of life in migraine. Neurology 1997;48(suppl 3):10-15.
51. Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well being of headache patient: measurement by the Medical Outcomes Study. JAMA 1989;262:907-913.
52. Ware J, Kosinski M, Keller SD. A 12-item short form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
53. Hopton JL, Hunt SM, Shiels C, Smith C. Measuring psychological well-being. The adapted General Well-Being Index in a primary care setting: a test of validity. Fam Pract 1995;12:452-460.
54. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37:53-55.
55. Damiano A. The sickness impact profile. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical research. Philadelphia: Lippincott-Raven, 1996:347-354.
56. Hurst B, Macclesfield U. Assessing outcomes of treatment for migraine headache using generic and specific measurements. Neurology 1998;50(suppl 4):180-181.
57. Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 1998;38:295-302.
58. Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD. Validation of a new quality of life questionnaire for acute migraine headache. Headache 1995;35:330-337.
59. Dahlof C, Bouchard J, Cortelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life. Pharmacoeconomics 1997;11(suppl 1):24-34.
60. Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia 1997;17:867-872.
61. Dahlof C. Assessing patient preference in migraine treatment. Cephalalgia 2001;21:791-795.